Skip to main content
Top
Published in: Clinical and Translational Oncology 8/2017

01-08-2017 | Review Article

The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review

Authors: A. Youroukou, I. Gkiozos, Z. Kalaitzi, I. Tsalafoutas, K. Papalla, A. Charpidou, V. Kouloulias

Published in: Clinical and Translational Oncology | Issue 8/2017

Login to get access

Abstract

To review the use of brachytherapy as an adjuvant therapy to reduce recurrences after sublobar resections and as a palliation to patients with inoperable disease. Α review of all published studies was performed to identify the recurrence rate after brachytherapy adjuvant to sublobar resection and assess the palliation of symptoms and the complications of brachytherapy as a palliative treatment. Most of the studies that we found about brachytherapy as an adjuvant therapy to sublobar resection due to patient’s poor cardiopulmonary reserve showed that brachytherapy offered low recurrence rate with low toxicity. Ten studies concerning palliative brachytherapy showed improvement of symptoms with good tolerance and good endoscopic response rates. Literature suggests that brachytherapy for inoperable symptomatic disease can be delivered for symptom improvement with acceptable toxicity. Brachytherapy as an alternative treatment option for lung cancer needs more investigation with more prospective trials.
Literature
1.
go back to reference Gunderson LL, Tepper JE. Clinical radiation oncology. 3rd ed. Amsterdam: Elsevier; 2012. p. 783. Gunderson LL, Tepper JE. Clinical radiation oncology. 3rd ed. Amsterdam: Elsevier; 2012. p. 783.
2.
go back to reference Halperin EC, Brady LW, Wazer DE, Perez CA. Perez and Brady’s: principles and practice of radiation oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1308. Halperin EC, Brady LW, Wazer DE, Perez CA. Perez and Brady’s: principles and practice of radiation oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1308.
3.
go back to reference Fay M, Poole CM, Pratt G. Recent advances in radiotherapy for thoracic tumours. J Thorac Dis. 2013;5(Suppl 5):S551–5.PubMedPubMedCentral Fay M, Poole CM, Pratt G. Recent advances in radiotherapy for thoracic tumours. J Thorac Dis. 2013;5(Suppl 5):S551–5.PubMedPubMedCentral
4.
go back to reference Santos R, Colonias A, Parda D, Trombetta M, Maley RH, Macherey R, et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer. Surgery. 2003;134(4):691–7.CrossRef Santos R, Colonias A, Parda D, Trombetta M, Maley RH, Macherey R, et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer. Surgery. 2003;134(4):691–7.CrossRef
5.
go back to reference Landreneau JP, Schuchert MJ, Weyant R, Abbas G, Wizorek JJ, Awais O, et al. Anatomic segmentectomy and brachytherapy mesh implantation for clinical stage I non-small cell lung cancer (NSCLC). Surgery. 2014;155(2):340–6.CrossRef Landreneau JP, Schuchert MJ, Weyant R, Abbas G, Wizorek JJ, Awais O, et al. Anatomic segmentectomy and brachytherapy mesh implantation for clinical stage I non-small cell lung cancer (NSCLC). Surgery. 2014;155(2):340–6.CrossRef
6.
go back to reference Voynov G, Heron DE, Lin CJ, Burton S, Chen A, Quinn A, et al. Intraoperative (125)I Vicryl mesh brachytherapy after sublobar resection for high-risk stage I non-small cell lung cancer. Brachytherapy. 2005;4(4):278–85.CrossRef Voynov G, Heron DE, Lin CJ, Burton S, Chen A, Quinn A, et al. Intraoperative (125)I Vicryl mesh brachytherapy after sublobar resection for high-risk stage I non-small cell lung cancer. Brachytherapy. 2005;4(4):278–85.CrossRef
7.
go back to reference Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron DE, et al. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. J Clin Oncol. 2014;32:2456–62.CrossRef Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron DE, et al. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. J Clin Oncol. 2014;32:2456–62.CrossRef
8.
go back to reference Chen A, Galloway M, Landreneau R, d’Amato T, Colonias A, Karlovits S, et al. Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1999;44(5):1057–63.CrossRef Chen A, Galloway M, Landreneau R, d’Amato T, Colonias A, Karlovits S, et al. Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1999;44(5):1057–63.CrossRef
9.
go back to reference Colonias A, Betler J, Trombetta M, Bigdeli G, Gayou O, Keenan R, et al. Mature follow-up for high-risk stage I non-small-cell lung carcinoma treated with sublobar resection and intraoperative iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2011;79(1):105–9.CrossRef Colonias A, Betler J, Trombetta M, Bigdeli G, Gayou O, Keenan R, et al. Mature follow-up for high-risk stage I non-small-cell lung carcinoma treated with sublobar resection and intraoperative iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2011;79(1):105–9.CrossRef
10.
go back to reference Tselis N, Ferentinos K, Kolotas C, Schirren J, Baltas D, Antonakakis A, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol. 2011;6:545–52.CrossRef Tselis N, Ferentinos K, Kolotas C, Schirren J, Baltas D, Antonakakis A, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol. 2011;6:545–52.CrossRef
11.
go back to reference Huang Q, Chen J, Chen Q, Lai Q, Cai S, Luo K, et al. Computed tomographic-guided iodine-125 interstitial implants for malignant thoracic tumors. Eur J Radiol. 2013;82(11):2061–6.CrossRef Huang Q, Chen J, Chen Q, Lai Q, Cai S, Luo K, et al. Computed tomographic-guided iodine-125 interstitial implants for malignant thoracic tumors. Eur J Radiol. 2013;82(11):2061–6.CrossRef
12.
go back to reference Zorlu AF, Selek U, Emri S, Gurkaynak M, Akyol FH. Second line palliative endobronchial radiotherapy with HDR Ir 192 in recurrent lung carcinoma. Yonsei Med J. 2008;49(4):620–4.CrossRef Zorlu AF, Selek U, Emri S, Gurkaynak M, Akyol FH. Second line palliative endobronchial radiotherapy with HDR Ir 192 in recurrent lung carcinoma. Yonsei Med J. 2008;49(4):620–4.CrossRef
13.
go back to reference Escobar-Sacristán JA, Granda-Orive JI, Gutiérrez Jiménez T, Delgado JM, Rodero Baños A, Saez Valls R. Endobronchial brachytherapy in the treatment of malignant lung tumours. Eur Respir J. 2004;24(3):348–52.CrossRef Escobar-Sacristán JA, Granda-Orive JI, Gutiérrez Jiménez T, Delgado JM, Rodero Baños A, Saez Valls R. Endobronchial brachytherapy in the treatment of malignant lung tumours. Eur Respir J. 2004;24(3):348–52.CrossRef
14.
go back to reference Kelly JF, Delclos ME, Morice RC, Huaringa A, Allen PK, Komaki R. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience. Int J Radiat Oncol Biol Phys. 2000;48(3):697–702.CrossRef Kelly JF, Delclos ME, Morice RC, Huaringa A, Allen PK, Komaki R. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience. Int J Radiat Oncol Biol Phys. 2000;48(3):697–702.CrossRef
15.
go back to reference Celebioglu B, Gurkan OU, Erdogan S, Savas I, Köse K, Kurtman C, et al. High dose rate endobronchial brachytherapy effectively palliates symptoms due to inoperable lung cancer. Jpn J Clin Oncol. 2002;32(11):443–8.CrossRef Celebioglu B, Gurkan OU, Erdogan S, Savas I, Köse K, Kurtman C, et al. High dose rate endobronchial brachytherapy effectively palliates symptoms due to inoperable lung cancer. Jpn J Clin Oncol. 2002;32(11):443–8.CrossRef
16.
go back to reference Macha HN, Wahlers B, Reichle C, von Zwehl D. Endobronchial radiation therapy for obstructing malignancies: ten years’ experience with iridium-192high-dose radiation brachytherapy afterloading technique in 365 patients. Lung. 1995;173(5):271–80.CrossRef Macha HN, Wahlers B, Reichle C, von Zwehl D. Endobronchial radiation therapy for obstructing malignancies: ten years’ experience with iridium-192high-dose radiation brachytherapy afterloading technique in 365 patients. Lung. 1995;173(5):271–80.CrossRef
17.
go back to reference Guarnaschelli JN, Jose BO. Palliative high-dose-rate endobronchial brachytherapy for recurrent carcinoma: the University of Louisville experience. J Palliat Med. 2010;13(8):981–9.CrossRef Guarnaschelli JN, Jose BO. Palliative high-dose-rate endobronchial brachytherapy for recurrent carcinoma: the University of Louisville experience. J Palliat Med. 2010;13(8):981–9.CrossRef
18.
go back to reference de Aquino Gorayeb MM, Gregório MG, de Oliveira EQ, Aisen S, Carvalho Hde A. High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: a quantitative assessment. Brachytherapy. 2013;12(5):471–8.CrossRef de Aquino Gorayeb MM, Gregório MG, de Oliveira EQ, Aisen S, Carvalho Hde A. High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: a quantitative assessment. Brachytherapy. 2013;12(5):471–8.CrossRef
19.
go back to reference Aumont-Le Guilcher M, Prevost B, Sunyach P, Pieffert D, Maingon P, Thomas L, et al. High-dose-rate brachytherapy for non-small-cell lung carcinoma: a retrospective study of 226 patients. Int J Rad Oncol Biol Phys. 2011;79:1112–6.CrossRef Aumont-Le Guilcher M, Prevost B, Sunyach P, Pieffert D, Maingon P, Thomas L, et al. High-dose-rate brachytherapy for non-small-cell lung carcinoma: a retrospective study of 226 patients. Int J Rad Oncol Biol Phys. 2011;79:1112–6.CrossRef
Metadata
Title
The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review
Authors
A. Youroukou
I. Gkiozos
Z. Kalaitzi
I. Tsalafoutas
K. Papalla
A. Charpidou
V. Kouloulias
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1635-0

Other articles of this Issue 8/2017

Clinical and Translational Oncology 8/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine